Five Quiet Years on Omalizumab: Testing Whether the Drug Is Still Doing the Work
A man who hasn't had an asthma exacerbation in five years on omalizumab wants to know if he still needs it. The honest answer, and the real disagreement, is that nobody can tell him for certain without actually finding out.
G.M., a 58-year-old retired ferry captain, started omalizumab five years ago after a stretch he still refers to only as "the bad years" — two ICU admissions for severe exacerbations in eighteen months, one of them close enough that his wife has never fully stopped bringing it up. Since starting the drug he has had zero exacerbations requiring oral steroids, stable spirometry, and a life that has, in his own words, "gone back to normal enough that I sometimes forget why I'm even still getting the shot."
That question — whether he still needs it — doesn't have a clean answer sitting in his chart, but it isn't unanswerable either. His FEV1 has held steady at 91% predicted for three consecutive years, his skin testing remains positive to the same perennial allergens as ever (his allergic sensitization itself doesn't go away, only its clinical expression can), and his current IgE, now suppressed by five years of therapy, is no longer a meaningful guide to what his untreated biology would look like today. The best available evidence on exactly his situation is XPORT, the randomized omalizumab-withdrawal trial, and it enrolled patients on the drug for five years or more — his own duration, not an approximation of it. Over the following year, 47.7% of those withdrawn stayed free of a protocol-defined exacerbation against 67% of those who continued, which means relapse was the slightly more likely outcome of stopping rather than the exception, and no pre-withdrawal marker in that trial distinguished who would relapse from who wouldn't.
He retired from the ferry three years ago, largely for unrelated reasons, and now spends most of his time restoring an old sailboat in his driveway — work he says he couldn't have managed during the bad years, when climbing on and off a deck left him short of breath before he'd done anything strenuous at all. He has no other major medical problem, takes no other daily medication, and has never missed a scheduled dose in five years, a detail his allergist notes partly because it rules out inconsistent dosing as a hidden explanation for how well he's done.
Shared decision-making visit, five years into stable therapy
I wouldn't recommend simply stopping. XPORT randomized patients with his exact profile — five years or more of stable omalizumab — to continue or withdraw, and rather more than half the withdrawal arm exacerbated within the following year, without a pre-withdrawal marker in that trial reliably predicting who. That's not a reason to keep every patient on the drug forever, but it is a reason to structure any discontinuation as a monitored trial rather than an unsupervised stop.
Given his specific history, I'd weight the relapse risk more heavily than the trial's average result suggests in the abstract. He's not a patient with a moderate exacerbation history; he had two ICU admissions before starting this drug, and XPORT's population was broader than that — it wasn't restricted to patients with a near-fatal history the way his is. I'd want a longer, more closely monitored taper than the trial's own withdrawal protocol before I'd be comfortable calling this safe to test.
You're right that XPORT is the best trial we have on this question — the disagreement is whether its average relapse rate, drawn from a broader population, should set the pace for a patient whose own pre-treatment history is more severe than most of that trial's enrollees.
Both of you are right about different parts of this. XPORT tells us discontinuation carries a real, non-trivial risk that no available marker predicts in advance — that argues against an abrupt, unmonitored stop for anyone, and doubly so for a patient with his history. But it doesn't argue for indefinite therapy either; five years of unnecessary treatment, if he no longer needs it, carries its own real cost in burden and expense that shouldn't be dismissed just because the drug is working.
The version that respects both facts is a structured interval extension rather than a stop: space his dosing interval out gradually, with spirometry and symptom tracking at each step, so any early sign of loss of control shows up while he's still on a meaningful dose rather than after a full washout — a genuine test of whether he still needs it, without recreating the abrupt-withdrawal scenario XPORT actually studied.
Agreed: dosing interval extended stepwise over the next several visits, with spirometry, symptom diary, and rescue-inhaler use tracked at each step as the actual test of whether he still needs the drug, rather than an all-or-nothing stop.
Not agreed: how large a symptom change should trigger reverting to his original interval versus continuing the extension trial for one more step. The pulmonologist wants a low threshold given his ICU history; the allergist would tolerate a somewhat larger symptom fluctuation before reverting, given how much unnecessary therapy costs him if the threshold is set too conservatively. Left for the two of them to agree case-by-case as each step's results come in.